This paper describes the rationale and design of the Novel START (Symbicort Turbuhaler Asthma Reliever Therapy) randomised controlled trial of inhaled corticosteroid (ICS)/fast-onset long-acting β agonist (LABA) reliever therapy in mild asthma.
Description of a real world study of the novel ICS/fast-onset LABA reliever therapy regimen in mild asthma http://ow.ly/WE3Yp
Clinical trial: This study is registered at www.anzctr.org.au with identifier ACTRN12615000999538. Universal Trial Number: U1111-1170-2118.
Support statement: This study is funded by a grant from AstraZeneca (reference number ESR 14-10452). The study was initiated and designed by the investigators prior to consultation with AstraZeneca. The global sponsor of the study is the Medical Research Institute of New Zealand (Wellington, New Zealand) (reference number: MRINZ/15/A1), which will take overall responsibility for the study conduct, monitoring and data management. Funding information for this article has been deposited with FundRef.
Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com
- Received October 12, 2015.
- Accepted December 12, 2015.
- Copyright ©ERS 2016